INS and Hyperglycemia: Our systematic review and meta-analysis demonstrated that the use of URAIs instead of standard insulin within HCL systems provides clinically meaningful improvements in glycemic control, particularly by significantly reducing nighttime hyperglycemia, both at moderate (TAR >180 mg/dL) and severe (TAR >250 mg/dL) levels.